{"entity":{"id":"nct07631884","kind":"trial","name":"Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor","aka":[],"tldr":"A phase 2 trial of trastuzumab rezetecan in gallbladder cancer and other biliary tract cancers, run by Haihua Yuan, not yet recruiting.","summary":"Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor is a phase 2 interventional study registered as NCT07631884 by Haihua Yuan, with a registry enrolment figure of 15 participants, started 2026-06-15 and due to reach its primary completion in 2028-12-31. Interventions recorded: Trastuzumab Rezetecan. Conditions listed: Solid Tumors, Neoplasms (Cancer / Tumors), Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, HER2 Expression, Biliary Tract Neoplasms, Endometrial Neoplasms, Urothelial Carcinoma (UC), Pancreatic Neoplasms, Colorectal Neoplasms, Gastric Neoplasms, Non-Small Cell Lung Carcinoma (NSCLC), Head and Neck Neoplasms, Cervical Neoplasms. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07631884","url":"https://clinicaltrials.gov/study/NCT07631884"}],"tags":["ctgov-ingest","gallbladder-deep-dive"],"related":[],"cancers":["gallbladder","cholangiocarcinoma","biliary-tract-cancer"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["trastuzumab-rezetecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07631884","phase":"2","setting":"Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor","sponsor":"Haihua Yuan","enrolled":15,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07631884/","neighbours":{"cancer":[{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/"},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"trastuzumab-rezetecan","kind":"drug","name":"Trastuzumab rezetecan","route":"/drugs/trastuzumab-rezetecan/"}],"term":[{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/"}]}}